Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

被引：86

作者：

Yu, Fei ^{[1
]}

Xiang, Rong ^{[1
]}

Deng, Xiaoqian ^{[1
]}

Wang, Lili ^{[2
]}

Yu, Zhengsen ^{[1
]}

Tian, Shijun ^{[1
]}

Liang, Ruiying ^{[1
]}

Li, Yanbai ^{[1
]}

Ying, Tianlei ^{[3
]}

Jiang, Shibo ^{[3
]}

机构：

[1] Hebei Agr Univ, Coll Life Sci, Baoding, Peoples R China

[2] Hebei Agr Univ, Res Ctr Chinese Jujube, Baoding, Peoples R China

[3] Fudan Univ, Sch Basic Med Sci, CAMS, Key Lab Med Mol Virol,MOE,NHC, Shanghai, Peoples R China

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期

基金：

中国国家自然科学基金;

关键词：

ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SPIKE PROTEIN; POTENT NEUTRALIZATION; VIRUS; IMMUNOPROPHYLAXIS; IDENTIFICATION; GENERATION; EPITOPES; FRAGMENT; VACCINE;

D O I：

10.1038/s41392-020-00318-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.

引用

页数：12

共 50 条

[21] Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate
Chen, Wen-Hsiang
Du, Lanying
Chag, Shivali M.
Ma, Cuiqing
Tricoche, Nancy
Tao, Xinrong
Seid, Christopher A.
Hudspeth, Elissa M.
Lustigman, Sara
Tseng, Chien-Te K.
Bottazzi, Maria Elena
Hotez, Peter J.
Zhan, Bin
Jiang, Shibo
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (03) : 648 - 658
[22] Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
He, YX
Zhou, YS
Liu, SW
Kou, ZH
Li, WH
Farzan, M
Jiang, SB
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 773 - 781
[23] Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies
Ye, Farong
Zhao, Jie
Xu, Peng
Liu, Xinliang
Yu, Jing
Shangguan, Wei
Liu, Jiazhi
Luo, Xiaosheng
Li, Cheng
Ying, Tianlei
Wang, Jing
Yu, Biao
Wang, Ping
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (23) : 12904 - 12910
[24] Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Deliyannis, Georgia
Gherardin, Nicholas A.
Wong, Chinn Yi
Grimley, Samantha L.
Cooney, James P.
Redmond, Samuel J.
Ellenberg, Paula
Davidson, Kathryn C.
Mordant, Francesca L.
Smith, Tim
Gillard, Marianne
Lopez, Ester
McAuley, Julie
Tan, Chee Wah
Wang, Jing J.
Zeng, Weiguang
Littlejohn, Mason
Zhou, Runhong
Chan, Jasper Fuk-Woo
Chen, Zhi-wei
Hartwig, Airn E.
Bowen, Richard
Mackenzie, Jason M.
Vincan, Elizabeth
Torresi, Joseph
Kedzierska, Katherine
Pouton, Colin W.
Gordon, Tom P.
Wang, Lin-fa
Kent, Stephen J.
Wheatley, Adam K.
Lewin, Sharon R.
Subbarao, Kanta
Chung, Amy W.
Pellegrini, Marc
Munro, Trent
Nolan, Terry
Rockman, Steven
Jackson, David C.
Purcell, Damian F. J.
Godfrey, Dale I.
EBIOMEDICINE, 2023, 92
[25] An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
Guo, Yan
He, Wenhui
Mou, Huihui
Zhang, Lizhou
Chang, Jing
Peng, Shoujiao
Ojha, Amrita
Tavora, Rubens
Parcells, Mark S.
Luo, Guangxiang
Li, Wenhui
Zhong, Guocai
Choe, Hyeryun
Farzan, Michael
Quinlan, Brian D.
MBIO, 2021, 12 (03):
[26] Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV
Panchal, Disha
Kataria, Jeena
Patel, Kamiya
Crowe, Kaytlyn
Pai, Varun
Azizogli, Abdul-Rahman
Kadian, Neil
Sanyal, Sreya
Roy, Abhishek
Dodd-o, Joseph
Acevedo-Jake, Amanda M.
Kumar, Vivek A.
ADVANCED THERAPEUTICS, 2021, 4 (10)
[27] SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?
Boskovic, Marko
Migo, William
Likic, Robert
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (11) : 4476 - 4478
[28] The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein
Aripov, V. S.
Volkova, N. V.
Taranin, A. V.
Mechetina, L. V.
Chikaev, N. A.
Nayakshin, A. M.
Nesmeyanova, V. S.
Isaeva, A. A.
Merkul'eva, Yu. A.
Shanshin, D. V.
Belenkaya, S. V.
Ilyichev, A. A.
Shcherbakov, D. N.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 175 (02) : 225 - 228
[29] Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, Bin
Zhang, Qi
Ge, Jiwan
Wang, Ruoke
Sun, Jing
Ge, Xiangyang
Yu, Jiazhen
Shan, Sisi
Zhou, Bing
Song, Shuo
Tang, Xian
Yu, Jinfang
Lan, Jun
Yuan, Jing
Wang, Haiyan
Zhao, Juanjuan
Zhang, Shuye
Wang, Youchun
Shi, Xuanling
Liu, Lei
Zhao, Jincun
Wang, Xinquan
Zhang, Zheng
Zhang, Linqi
NATURE, 2020, 584 (7819) : 115 - +
[30] Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies
Kang, Hyangju
Kim, Daniel
Min, Kyungmin
Park, Minhee
Kim, Seok-Hyun
Sohn, Eun-Ju
Choi, Bo-Hwa
Hwang, Inhwan
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2022, 11 (03) : 285 - 289

← 1 2 3 4 5 →